Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
Public ClinicalTrials.gov record NCT06998056. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open Label, 4-Week, Safety Study of Roflumilast Cream 0.05% Administered Once Daily in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
Study identification
- NCT ID
- NCT06998056
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Arcutis Biotherapeutics, Inc.
- Industry
- Enrollment
- 101 participants
Conditions and interventions
Conditions
Interventions
- ARQ-151 cream 0.05% Drug
Drug
Eligibility (public fields only)
- Age range
- 3 Months to 2 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2025
- Primary completion
- Dec 3, 2025
- Completion
- Dec 3, 2025
- Last update posted
- Dec 9, 2025
2025
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arcutis Clinical Study Site 208 | Birmingham | Alabama | 35244 | — |
| Arcutis Clinical Study Site 221 | Bryant | Arkansas | 72022 | — |
| Arcutis Clinical Study Site 214 | Fountain Valley | California | 92708 | — |
| Arcutis Clinical Study Site 209 | Rancho Santa Margarita | California | 92688 | — |
| Arcutis Clinical Study Site 207 | Coral Gables | Florida | 33146 | — |
| Arcutis Clinical Study Site 217 | Delray Beach | Florida | 33484 | — |
| Arcutis Clinical Study Site 213 | Jacksonville | Florida | 32256 | — |
| Arcutis Clinical Study Site 223 | Boise | Idaho | 83706 | — |
| Arcutis Clinical Study Site 219 | West Lafayette | Indiana | 47906 | — |
| Arcutis Clinical Study Site 212 | Minneapolis | Minnesota | 55112 | — |
| Arcutis Clinical Study Site 211 | Portsmouth | New Hampshire | 03801 | — |
| Arcutis Clinical Study Site 220 | Mason | Ohio | 45040 | — |
| Arcutis Clinical Study Site 206 | Portland | Oregon | 97239 | — |
| Arcutis Clinical Study Site 222 | Summerville | South Carolina | 29486 | — |
| Arcutis Clinical Study Site 210 | Bellaire | Texas | 77401 | — |
| Arcutis Clinical Study Site 224 | Fort Worth | Texas | 76244 | — |
| Arcutis Clinical Study Site 202 | San Antonio | Texas | 78218 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06998056, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 9, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06998056 live on ClinicalTrials.gov.